Abstract: Provided is a vehicle-road cooperation street lamp for an urban road. The vehicle-road cooperation street lamp for an urban road comprises a vehicle-road cooperation street lamp body, wherein a first supporting plate is transversely arranged on the front side of the top of the vehicle-road cooperation street lamp body, a transmission cavity is transversely formed in the first supporting plate, a first electric telescopic rod is transversely arranged in the inner cavity of the transmission cavity and located on the outer wall of the vehicle-road cooperation street lamp body, and a rack plate is transversely arranged on the front side of the first electric telescopic rod and located in the transmission cavity.

Abstract: Provided are a traditional Chinese medicine ointment for preventing and treating mastitis in dairy cows and a preparation method thereof, belonging to the technical field of veterinary traditional Chinese medicines. The traditional Chinese medicine ointment includes raw materials in parts by mass: 20-30 parts of dandelion, 20-30 parts of herba patriniae, 10-16 parts of Caulis Lonicerae Japonicae, 0.5-1 part of borneol, 0.03-0.05 part of polypeptide, 40-50 parts of auxiliary emulsifier, 40-50 parts of liquid paraffin and 100-130 parts of white vaseline. An amino acid sequence of the polypeptide is: Phe Phe Arg Lys Val Leu Lys Leu Ile Arg Lys Ile Trp Arg (SEQ ID NO. 1). In the application, dandelion, herba patriniae, Caulis Lonicerae Japonicae and borneol 1 are mixed, and polypeptide is added at the same time to prepare ointment.

Abstract: One or more aspects of the present disclosure provide methods for discharging spent batteries. The methods may include coating anode electrodes and cathode electrodes of the spent batteries with at least one catalyst layer. The catalyst layer may facilitate consistent and rapid discharge of the spent batteries. The spent batteries may be processed using an electrolyte solution to discharge the spent batteries. The electrolyte solution may include one or more suitable electrolytes that do not cause electrode corrosion during the discharge of the spent batteries. For example, the electrolytes may include a mixture of Na3PO4, water, co-solvent (e.g., ethylene glycol), and at least one surfactant, such as polyoxymethylene glycol octylphenol ethers, dioctyl sodium sulfosuccinate, perfluorooctanesulfonate, etc.

Abstract: The present disclosure discloses an optical imaging lens assembly, sequentially from an object side to an image side along an optical axis, including: a first lens having refractive power, an object-side surface thereof is concave, and an image-side surface thereof is convex; a second lens having refractive power; a third lens having refractive power; a fourth lens having refractive power; a fifth lens having negative refractive power, and an object-side surface thereof is concave; a sixth lens having positive refractive power; and a seventh lens having refractive power. A total effective focal length f of the optical imaging lens assembly and an effective focal length f3 of the third lens may satisfy f3/f>1.49.

Abstract: The present disclosure discloses an optical imaging system, sequentially from an object side to an image side of the optical imaging system along an optical axis, including: a first lens having refractive power; a second lens having negative refractive power; a third lens having refractive power; a fourth lens having positive refractive power; a fifth lens having refractive power; a sixth lens having refractive power; and a seventh lens having refractive power, a concave object-side surface, and a concave image-side surface. Half of a diagonal length ImgH of an effective pixel area on an imaging plane of the optical imaging system may satisfy ImgH>6.0 mm. A total effective focal length f of the optical imaging system and an entrance pupil diameter EPD of the optical imaging system may satisfy f/EPD<1.9.

Abstract: An optical imaging system includes an optical lens group including, sequentially along an optical axis from an object side to an image side, a first lens, a second lens, a third lens, and a fourth lens; a lens barrel, the optical lens group is accommodated in the lens barrel; and a plurality of spacers including at least two spacers disposed between the third lens and the fourth lens; the diameter D of the lens barrel at an end towards the object side and a maximum effective radius DT11 of an object-side surface of the first lens satisfy 2×DT11/D?0.5.

Abstract: A method for evaluating adverse reaction of sesquiterpenoids in zedoary turmeric oil is performed successively according to the following steps: (1) preparing a hemoglobin (Hb) solution and a to-be-determined solution; (2) taking Hb solutions with a same volume and respectively adding the same volume of the to-be-determined solution or normal saline thereto, mixing well and standing; (3) determining absorbance with a microplate reader, and comparing the absorbance of a to-be-determined solution group with the absorbance of a normal saline group to obtain a value r; wherein if r>1.5, then the result indicates that the concentration of the to-be-determined solution has a risk of causing dyspnea; wherein, r = OD OD Hb ; in the formula, OD is an absorbance at 280 nm wavelength of the to-be-determined solution after interacting with Hb; ODHb, is an absorbance at 280 nm wavelength of a blank control of normal saline after interacting with Hb.

Abstract: A technology of 3D printing integration of hard materials and cells, a preparation of bone-repair functional module with osteogenic microenvironment, bone organoid method and the application of quick repair of bone defects are provided. A preparation method of biological microenvironmental factors as independent osteogenic factors is further provided. The present integrated 3D printing technology realizes 3D printing of cells and hard materials synchronously by adjusting the temperature, so as to build a real sense of biomimetic bone tissue, which can be customized according to the specific defects and clinical needs of patients.

Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

Abstract: The present disclosure discloses an optical imaging lens group including, sequentially from an object side to an image side along an optical axis, a first lens having positive refractive power with a convex object-side surface; a second lens having refractive power; a third lens having refractive power; a fourth lens having refractive power; a fifth lens having refractive power; and a sixth lens having negative refractive power with a concave object-side surface and a convex image-side surface. A total effective focal length f of the optical imaging lens group, an entrance pupil diameter EPD of the optical imaging lens group and half of a maximal field-of-view Semi-FOV of the optical imaging lens group satisfy: f/EPD<2, and f*tan(Semi-FOV)>4.5 mm.

Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.

Abstract: The present invention provides novel compounds (e.g., compounds of Formula I) which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Abstract: The present disclosure relates to the field of medical technology, and in particular to a composition and the use thereof in the manufacture of a medicament for treating cancer. The present disclosure provides a composition containing a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof, and a tyrosine kinase activity inhibitor. The present disclosure shows through in vivo and in vitro anti-tumor tests that, based on the inhibitory effect of the tyrosine kinase activity inhibitor targeting VEGFR, EGFR and other receptor tyrosine kinases, the combination of Sotagliflozin and a tyrosine kinase activity inhibitor may exhibit a synergistic inhibitory effect on tumors, and the efficacy of the combination is significantly better than that of a single drug.

Abstract: The present disclosure relates to the field of medical technology, and in particular to use of a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof in the manufacture of a medicament for treating cancer. By testing the inhibitory effect on a variety of tumor cells, the results show that the compound of formula I has an inhibitory effect on tumor cells, with an IC50 of 40.77 ?M-182.5 ?M. In animal experiments, the compound of formula I shows a good inhibition effect on tumor volume, which is very significantly different from that of the solvent control group, p<0.05.

Abstract: The present invention relates to the field of medical technology, in particular to a composition for treating cancer and use and medicament thereof. The composition comprises an SGLT1 inhibitor and a VEGFR2 inhibitor. The present invention finds that SGLT1 interacts with VEGFR2 to promote the development and progression of tumors; the present invention also finds that a composition of a VEGFR2 targeting inhibitor and an SGLT1 inhibitor has a synergistic anti-tumor effect, and the composition of the VEGFR2 targeting inhibitor and the SGLT1 targeting inhibitor can be used in cancer treatment.

Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Abstract: The present disclosure discloses an optical imaging lens group. The optical imaging lens group comprises, sequentially along an optical axis from an object side to an image side, a first lens, a second lens, a third lens, a fourth lens, a fifth lens, a sixth lens, a seventh lens and an eighth lens, wherein the first lens, the second lens, the third lens, the fourth lens, the fifth lens, the sixth lens, the seventh lens and the eighth lens have refractive powers. At least one lens in the first lens to the eighth lens has a non-rotationally symmetric aspheric surface; a total effective focal length fy of the optical imaging lens group in a Y-axis direction and a total effective focal length fx of the optical imaging lens group in an X-axis direction satisfy: fy/fx<0.8; and an f-number Fnoy of the optical imaging lens group in the Y-axis direction satisfies: Fnoy<2.9.